Whole-genome sequencing as a tool for studying the microevolution of drug-resistant serial Mycobacterium tuberculosis isolates


To cite this version:

HAL Id: hal-03836718
https://hal.archives-ouvertes.fr/hal-03836718
Submitted on 3 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Whole-genome sequencing of serial *Mycobacterium tuberculosis* isolates from previously treated patients


a- Núcleo de Pesquisa em Microbiologia Médica, Faculdade de Medicina, Universidade Federal do Rio Grande, Rio Grande, Rio Grande do Sul, Brazil

b- Hospital Sanatório Partenon, Secretaria Estadual de Saúde do Rio Grande do Sul (HSP SES/RS), Porto Alegre, Rio Grande do Sul, Brazil

c- Centro de Desenvolvimento Científico e Tecnológico, Porto Alegre, Rio Grande do Sul, Brazil

d- Programa de Pós-graduação em Biologia Celular e Molecular, Universidade Luterana do Brasil, Porto Alegre, Brazil

e- Combi-Lab – Grupo de Biologia Computacional, Centro de Ciências Computacionais C3, Universidade Federal do Rio Grande, Rio Grande, Rio Grande do Sul, Brazil

f- London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom

g- Pathogen Genomics Laboratory, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia

h- Research Center for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan

i- Research Institute for Medicines - iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal

j- Unidade de Microbiologia Médica, Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Lisboa, Portugal
ABSTRACT

Treatment of drug-resistant tuberculosis requires extended use of more toxic and less effective drugs and may result in retreatment cases due to failure, abandonment or disease recurrence. It is therefore important to understand the evolutionary process of drug resistance in Mycobacterium tuberculosis. We here in describe the microevolution of drug resistance in serial isolates from six previously treated patients. Drug resistance was initially investigated through phenotypic methods, followed by genotypic approaches. The use of whole-genome sequencing allowed the identification of mutations in the katG, rpsL and rpoB genes associated with drug resistance, including the detection of rare mutations in katG and mixed populations of strains. Molecular docking simulation studies of the impact of observed mutations on isoniazid binding were also performed. Whole-genome sequencing detected 266 single nucleotide polymorphisms between two isolates obtained from one patient, suggesting a case of exogenous reinfection. In conclusion, sequencing technologies can detect rare mutations related to drug resistance, identify subpopulations of resistant strains, and identify diverse populations of strains due to exogenous reinfection, thus improving tuberculosis control by guiding early implementation of appropriate clinical and therapeutic interventions.

Keywords: Catalase assay, Exogenous reinfection, Microevolution, Resistance, Whole genome sequencing.
1. INTRODUCTION

Tuberculosis (TB) is the second leading cause of death from infectious disease worldwide. This scenario is aggravated by the increase of TB cases with drug-resistant (DR) strains of *Mycobacterium tuberculosis* [1-3]. Particularly disturbing is the increase of cases with multidrug-resistant (MDR) strains, defined as resistant at least to rifampicin and isoniazid, and extensively resistant strains, which in addition to MDR, are also resistant to a fluoroquinolone and an injectable second-line drug. TB with DR strains requires a prolonged treatment regimen and the use of more expensive, toxic and less effective drugs, which increases the number of cases of retreatment [4].

TB with DR strains is most frequent in previously treated patients, and it is important to know the susceptibility profile of the strains obtained from these patients [5, 6]. Identifying whether retreatment cases are caused by failure, abandonment or even by a new episode of the disease after clinical cure (recurrence) is important for therapeutic success as well TB control in the community [7-11]. Recurrent cases are the result of endogenous reactivation (relapse of primary infection) or exogenous reinfection (infection with a new bacillary load) [4, 12-14].

Several methods have been used to evaluate the genetic diversity of *M. tuberculosis* strains, although for molecular epidemiology proposals *Mycobacterial Interspersed Repeating Unit - Variable Number of Tandem* (MIRU-VNTR) is a useful tool [15-17]. More recently, whole-genome sequencing (WGS), in addition to identifying the genetic relationships among strains with high accuracy [18-22], is an important tool to recognize the evolution of different populations of microorganisms [23, 24], drug susceptibility and resistance profiles [25-28].

Furthermore, WGS has allowed us to more deeply understand the evolutionary process that involves drug resistance in *M. tuberculosis*, identify single nucleotide polymorphisms (SNPs) related to drug resistance and biological cost mitigation [29-31]. Here, we describe the microevolution of drug resistance of serial isolates of *M. tuberculosis* from patients who previously underwent TB treatment.

2. METHODOLOGY

2.1 Samples

Thirteen strains of *M. tuberculosis* obtained from six patients who previously underwent TB treatment that showed drug resistance evolution during treatment were studied. These strains were recovered from the strain collection of the Hospital Sanatorio Partenon (HSP), the Center of Reference for Cases of Treatment of TB Resistance in the state of Rio Grande do Sul, located in southern Brazil. TB patients recruited at HSP were sampled at different times during treatment with two or more isolates obtained.
2.2 Data collection

Clinical and epidemiological data of the six patients included in this study were obtained from the Department of Phthisiology of HSP. This study was approved by the Research Ethics Committee of the State Foundation for Production and Health Research (no. 04/2012).

2.3 Cultivation and extraction of DNA

The strains were cultivated in Ogawa-Kudoh medium and incubated at 37°C for approximately four weeks. After growth, the cultures were used to perform the drug susceptibility test (DST) and extraction of genomic DNA by the cetyl-trimethyl-ammonium bromide-sodium chloride method [32].

2.4 Drug susceptibility testing

The DST was initially performed by the proportion method (PM) [33] in the central laboratory of HSP during the treatment of the patients studied before the realization of this study. In this work, DST was performed on first-line anti-TB drugs by a BATEC 320 MGIT (Mycobacteria Growth Indicator Tube) system according to the manufacturer’s instructions (Becton, Dickinson and Company-USA). The concentrations used for each antimicrobial tested were 0.1 µg/ml for isoniazid, 1.0 µg/ml for streptomycin and rifampicin, 5.0 µg/ml for ethambutol and 100 µg/ml for pyrazinamide. Replication of these methods was performed to confirm conflicting results detected by WGS.

2.5 Catalase assays

We performed two tests in duplicate to evaluate the activity of the catalase enzyme in strains of *M. tuberculosis* (A1 and A2), in which one presented a mutation in a stop codon in the *katG* gene and was susceptible to isoniazid and the second presented a mutation in the same codon and was resistant to isoniazid by phenotypic methods.

2.5.1. Catalase test

Colonies of *M. tuberculosis* strains were removed from Ogawa-Kudoh cultures after 7 to 10 days of growth and inoculated in 0.5 mL of phosphate solution (0.041 M Na$_2$HPO$_4$, 0.02 M KH$_2$PO$_4$ [pH 7.0]). A solution containing equal amounts of 30% hydrogen peroxide and 10% Tween 80 was prepared, and 0.5 mL of this solution was added to a 0.5 mL suspension of mycobacteria. Foam production is indicative of catalase enzyme activity, while its absence demonstrates the loss of enzyme activity [34].

2.5.2. Semiquantitative catalase test
For the semiquantitative analysis of catalase enzyme activity, *M. tuberculosis* strains were grown on Ogawa-Kudoh medium cultures in screw-capped tubes for 14 days. One milliliter of a 30% hydrogen peroxide and 10% Tween 80 solution in a 1:1 ratio was added to the surface of growth. After 5 minutes, the height (in millimeters) of the produced column of foam was measured with a ruler, and the results were interpreted. Foam production in excess of 45 mm is considered catalase positive and < 45 mm catalase negative [35].

2.6 Genotyping

To study the evolution of drug resistance, all strains were genotyped by the MIRU-VNTR 24 loci method [16], to evaluate whether serial isolates of each patient had the same genotypic profile. Alterations in the MIRU-VNTR profile in two or more loci were considered different clonal populations [14, 36].

2.7 Whole-genome sequencing

The genomic DNA extracted from each strain of *M. tuberculosis* was sequenced using the Illumina HiSeq 2500 (paired-end 100-150 bp reads) platform, according to the manufacturer’s instructions (Illumina, San Diego, CA, USA).

2.8 Bioinformatics analysis of whole-genome sequencing

The raw reads obtained through WGS were submitted to the Trimomatic program to remove low-quality bases and assure the robustness of the analysis effectuated and as quality control of the sequences obtained [37]. The sequence data were mapped with the reference genome of *M. tuberculosis* H37Rv (GenBank, Ref. NC000962.3) using the Burrows-Wheeler Aligner program. The average reading coverage was approximately 99% of the whole reference genome, and the mean depth ranged from 2.7x to 671.2x (median: 283.7x) [38].

The allele variants, SNPs and insertions/deletions (INDELs) were identified through the SAMTools and Genome Analysis Toolkit programs based on the mapping performed [39, 40]. We analyzed genes and their promoter regions that are known to be associated with resistance to anti-TB drugs and compensatory mutations by the presence of SNPs and their percentages in all mapped reads. In this study, we assumed that cases were exogenous reinfections when there was a difference of >10 SNPs, but reinfections with the same clonal strain cannot be excluded [41].

2.9 In silico spoligotyping

Spoligotypes were generated in silico using SpolPred software [42]. Lineages (CLADE) and Spoligotype International Type (SITs) were classified according to the online SITVIT WEB database.
Changes in the profile of spoligotyping were considered to identify different clonal populations [14, 36].

2.10 Definitions

First-line anti-TB drugs: ethambutol, isoniazid, pyrazinamide, rifampicin and streptomycin.

Retreatment cases: patients who have already been treated for TB for 30 days or more. There are three types of retreatment cases: (1) a patient previously treated for TB and their most recent course of treatment failed (treatment after failure); (2) a patient previously treated for TB who returns to treatment having previously defaulted (treatment after abandonment); and (3) a patient who was previously declared cured or treatment completed and is diagnosed with bacteriologically positive (sputum smear or culture) TB (relapse) [4].

Treatment cure: Patients who presented two bacilloscopy negatives during treatment. In the absence of expectoration, the cure is based on clinical data and complementary tests [44].

2.11 Molecular docking simulations

To study the effect of the identified mutations on katG protein structure (A1 and A2 strains) and to evaluate how these mutations can impact the molecular interactions with isoniazid, we generated models for these protein structures and performed molecular docking simulations. For this, we needed the protein and ligand structures. The isoniazid (INH, ligand) structure was obtained from PubChem with CID 3767. The three protein structures of katG: wild type (wt), A1 D375 stop codon (D375X) and A2 (D735Y), were modeled by Phyre 2 [45]. The katG wt is available in the Protein Data Bank (PDB ID: 1SJ2); however, this structure has missing residues (1-23) and was included in the modeling step. To validate our models, the software Verify3D [46] and Procheck [47] were used. Procheck is a suite of programs to check the stereochemical quality of protein structures by analyzing overall and residue-by-residue geometry. Verify3D measures the compatibility of a protein model with its own amino acid sequence and according to this evaluation; a good model has at least 80% of the amino acids with scores >= 0.2 in the 3D/1D profile.

After obtaining the structures, we prepared them for docking using Auto Dock Tools [48]. We decided to perform docking simulations with and without HEM as part of the receptor structures. Thus, to prepare these for docking, we used VMD [49] to superpose the protein models with PDB ID 1SJ2 to pose the HEM on these structures.

The molecular docking simulations were performed with Vina [50] considering a grid box defined with size of x=36 Å, y=24 Å and z=40 Å, center in x= 74.067, y=38.579 and z=41.149 and exhaustiveness equal to 256. VMD and Discovery Studio [51] were used to analyze the results and generate the figures.
3. RESULTS

Because the study evaluated the microevolution of serial isolates obtained from each patient, the results are presented individually, with each patient identified by a letter. The clinical data of these patients were collected from medical records and are presented in Table 1.

3.1 Patient A

The first episode of TB in patient A occurred in 2010/03, when the treatment regimen with first-line antimicrobials: rifampicin, isoniazid and pyrazinamide (RHZ) was started. In the fifth month, the patient abandoned the treatment. Three months (2010/11) after the first episode, the patient returned to the health service, when the first strain (A1) was isolated and characterized as susceptible to first-line anti-TB drugs. It is not known if the patient began treatment at this moment, but after five months (2011/04), the patient returned to the health service with clinical signs of TB. At this time, a second strain (A2) was isolated (2011/04), which showed resistance to isoniazid by proportion and MGIT methods; treatment with RHZ was reintroduced and optimized by the addition of ethambutol. However, after five months, treatment failure was identified, with recurrence of symptoms and positive microscopy for acid-fast bacilli. For this reason, in 2011/10, a new therapeutic regimen was introduced with streptomycin, ethambutol, levofloxacin, terizidone and pyrazinamide (SELTZ) [44]. The treatment was successfully completed after 18 months with clinical cure (Figure 1).

The spoligotyping data were identical for both isolates, A1 and A2 (Table 2), in addition, MIRU-VNTR had variation in a single locus, and WGS presented a difference of 4 SNPs/year (Table 3). These genotypic data allowed us to infer that both episodes of disease were caused by the same strain [19, 52-56].

The WGS data analysis detected two mutations in katG in a codon already described as associated with resistance to isoniazid [57-63]. Interestingly, the first isolate was phenotypically susceptible and presented a stop codon (D735X) in 100% of the population. In the second isolate (A2), the D735Y mutation was identified in 41% of the population and was phenotypically resistant to isoniazid (Table 4). In addition, G594E rpoC was identified in both A1 and A2, and a mutation in the ahpC promoter region (C-54T) was found only in A2 (Table 4) [64-67].

Considering the difference in the susceptibility profiles of both strains, with a variation in the same codon in relation to H37Rv, we more deeply investigated these differences. Table 5 presents the results concerning new tests performed with a new culture of both strains. The MIC confirmed the susceptibility profile determined previously by PM. Using the Sanger method, mutations in katG were confirmed with the stop codon in the susceptible strain and tyrosine in the resistant strain. In relation to the catalase test, A2 did not present catalase activity. This same strain presented a mutation in the ahpC promoter region (C-54T).
We also performed molecular docking simulations to investigate the differences between katG wt, A1 (D735X) and A2 (D735Y) mutation interactions with isoniazid. First, we generated protein structure models for katG wt, A1 (D735X) and A2 (D735Y) using Phyre2 [45]. We evaluated the obtained models using the Verify3D averaged 3D-1D score, where katG wt has 94.59% of its residues >= 0.2, D735X has 92.10% of its residues >= 0.2 and D735Y has 91.22% of the residues >= 0.2 [46]. According to Prochek evaluation (Ramachadran plots), katG wt has 89.6% residues in most favorable regions, 9.2% in additional favorable regions, 0.7% generously favorable regions and only 0.7% disallowed regions; katG D735X presented 89.6% residues in most favorable regions, 9.1% in additional favorable regions, 0.8% generously favorable regions and only 0.5% disallowed regions; and katG D735Y Ramachandran plots showed 89.8% residues in most favorable regions, 9.0% in additional favorable regions, 1.0% generously favorable regions and only 0.2% disallowed regions [45, 46].

Thus, based on the evaluation results, we can consider the proposed models for katG wt, A1 (D735X) and A2 (D735Y) to be good for docking simulations. We performed docking simulations with Vina [50] considering the three protein models with HEM as part of their structures (with HEM) and not (without HEM) and INH as ligand. Table 6 presents the docking results: columns 2 and 4 describe the best free energy of binding (FEB) scored predicted by Vina (in kcal/mol), and columns 3 and 5 describe the protein residues interacting with INH (predicted by Discovery Studio [51]). Regarding FEB, we can observe that all of the scores are similar and varied from -6.4 to -7.0 kcal/mol.

Figure 2 shows the best docked positions for INH – katG models, with HEM (A, C, E) and without HEM (B, D, F). In terms of the final docked INH position, for katG wt with and without HEM (Figure 2 A and B), the best position is close to amino acid 735 highlighted in yellow, a different region observed for both A1 (D735X) (Figure 2 C and D) and A2 (D735Y) (Figure 2 E and F). Although A1 (D735X) and A2 (D735Y) interact with INH at another site, there are no key differences between them even though we observe variations in their susceptibility profiles. The results for simulations without HEM (Table 6, Figure 2 D and F) showed that both mutations interacted with the amino acids ASP93, ASP94, HIS97, LEU101, GLY273 and LYS274. However, considering the docking results with HEM, we can observe that A2 D735Y TRP 107 shares a hydrogen bond with INH and is not present in A1 D735X-INH.

3.2 Patient B

The first episode of TB in patient B occurred in 2005/03, when the first-line treatment regimen with RHZ was started. In the ninth month, treatment failure was detected with positive bacilloscopy. A new therapeutic regimen was then introduced with streptomycin, ethambutol, ethionamide and pyrazinamide (SEEtZ). However, the patient abandoned this treatment four months later. In 2006/09,
he returned to the health service with clinical signs of TB, when the first strain (B1) was isolated and characterized as susceptible to first-line anti-TB drugs by both phenotypic methods. Therefore, the previous SEEtZ treatment was reintroduced but proved to be ineffective eight months later, with bacilloscopy positivity detected. In 2007/06, treatment was optimized by the addition of rifampicin and isoniazid (RHSEEtZ). At this time, a second strain (B2) was isolated, which showed susceptibility to first-line anti-TB drugs by PM. However, in this study, resistance to streptomycin was detected by the MGIT method. As PM did not detect, streptomycin resistance in strain B2, the therapeutic regimen with RHSEEtZ was continued. After 12 months, treatment failure was diagnosed with positive bacilloscopy. In 2008/07, a third strain (B3) was isolated that was resistant to streptomycin and was now also detected by PM. A new therapeutic regimen was introduced with amikacin, ethambutol, ofloxacin, terizidone and pyrazinamide (AEOTZ). The treatment was successfully completed after 18 months, achieving a clinical cure (Figure 3).

The MIRU-VNTR and spoligotyping data were identical for the three isolates (Table 2), in addition the WGS presented a difference of 2.7 SNPs/year between B2 and B3 (Table 3). These genotypic data allowed us to infer that all episodes of disease were caused by the same strain [19, 52-56].

The WGS data analysis detected a K43R mutation in the rpsL gene related to streptomycin resistance [68-74]. Interestingly, this mutation was identified in 29% of the population of B1 and B2 strains, while 100% of the population of B3 presented the same mutation (Table 4).

3.3 Patient C

The first episode of TB of patient C occurred in 2009/05, when the regimen with RHZ was started. After the sixth month, treatment failure was diagnosed with positive bacilloscopy. This patient only returned to the health service in 2010/06, presenting clinical signs of TB, and treatment with RHZ was reintroduced and optimized by the addition of ethambutol. In 2010/09, the first strain (C1) was isolated, and PM was identified as susceptible to all first-line drugs, however resistance to isoniazid was detected by MGIT. As isoniazid resistance was not detected at the time of isolation, the therapeutic regimen with RHZE was maintained. After five months treatment failure was detected. In 2011/03, a second strain (C2) was isolated, which was resistant to isoniazid by proportion and MGIT methods. A new therapeutic regimen was then introduced with SELTZ, resulting in clinical cure after 18 months (Figure 4).

The MIRU-VNTR and spoligotyping data were identical for both isolates, C1 and C2 (Table 2), and there was no difference in the numbers of SNPs/year among isolates (Table 3). These genotypic data allowed us to infer that both episodes of disease were caused by the same strain [19, 52-56].
The WGS data analysis detected a Y337C mutation in the katG gene, described as associated with resistance to isoniazid [35, 60, 75]. This mutation was identified in both strains phenotypically resistant to isoniazid (C1 and C2) in 99% and 100% of the population, respectively (Table 4).

3.4 Patient D

The first episode of TB of patient D occurred in 2008/05, when the first-line treatment regimen with RHZ was started; however, a month later, the patient abandoned the treatment. After two months (2008/08), the patient returned to the health service, where treatment with RHZ was reintroduced; however, a month later, the patient abandoned treatment again. In 2008/11, the patient returned to health service with clinical signs of TB, when the first strain (D1) was isolated and showed susceptibility to all first-line anti-TB drugs. At this time, the treatment with RHZ was reintroduced, but in the second month, the patient was missing. In 2009/09, this patient returned, still presenting clinical signs of TB, and was treated with RHZ, but after three months (2009/12), the patient abandoned the treatment again. The patient was missing until 2010/05, at this time, when he returned to the health service. At this time, a new strain (D2) was isolated, a new therapeutic regimen was introduced with SEEtZ, and the D2 strain was phenotypically identified as isoniazid resistant. The treatment was successfully completed after 18 months with clinical cure (Figure 5).

The MIRU-VNTR data were identical for both isolates, D1 and D2, but the spoligotyping profile was different in the second strain (Table 2). The WGS data also showed a large difference in the number of SNPs (204.6 SNPs/year) between the D1 and D2 strains (Table 3). These genotypic data allowed us to infer that the episodes of disease may have been caused by two genetically distinct strains [14, 36, 41, 52, 76-78].

The WGS data analysis detected a N138H mutation in the katG gene, described as associated with resistance to isoniazid [60, 79-81]. This mutation was identified in 100% of the population of the strain phenotypically resistant to isoniazid (D2) (Table 4). In addition, G594E rpoC was identified in both D1 and D2 (Table 4) [64-67].

3.5 Patient E

The first episode of TB of patient E occurred in 2005/06, when the first-line treatment regimen with RHZ was started. However, this patient developed hepatic side effects, and a new therapeutic regimen was introduced with streptomycin, ofloxacin and ethambutol (SOE) [44]. This treatment was successfully completed after 12 months with clinical cure. In 2007/12, he returned to the health service and was diagnosed with a new case of TB, where a new therapeutic regimen was introduced with streptomycin, isoniazid and ethambutol (SHE). During the eighth month, treatment failure was diagnosed with positive bacilloscopy. This patient was missing and returned in 2009/09; at this time,
a new therapeutic regimen was introduced with streptomycin, rifampicin and pyrazinamide (SRZ). After twelve months (2010/09), this treatment proved to be ineffective when a first strain (E1) was isolated and showed resistance to isoniazid. In 2011/01, a new therapeutic regimen was introduced with amikacin, levofloxacin, terizidone, ethambutol, ethionamide and pyrazinamide (ALTEtZ). Due to the persistence of clinical signs of TB after three months, a second strain (E2) was isolated, and additional resistance to rifampicin was detected. Treatment with ALTEtZ was maintained for nine months, resulting in a clinical cure (Figure 6).

The MIRU-VNTR and spoligotyping data were identical for both isolates, E1 and E2 (Table 2), in addition the WGS presented a difference of 3.3 SNPs/year (Table 3). These genotypic data allowed us to infer that both episodes of disease were caused by the same strain [19, 52-56].

The WGS data analysis detected the mutations N138H in the katG gene and H445D in the rpoB gene, described as associated with resistance to isoniazid and rifampicin, respectively [60, 79-87]. The N138H mutation was identified in 100% of the population of the strains phenotypically resistant to isoniazid (E1 and E2). Only the E2 strain presented the H445D mutation in 99% of the strain population phenotypically resistant to rifampicin. In addition, the G594E mutation was also identified in the rpoC gene (Table 4) [64-67].

3.6 Patient F

The first episode of TB in patient F occurred in 2006/01, when the first-line treatment regimen with RHZ was started. The treatment was successfully completed after six months, with clinical cure. In 2009/04, the patient returned to the health service with clinical signs of TB, when the first strain (F1) was isolated and was susceptible to first-line anti-TB drugs. At this time, treatment with RHZ was reintroduced but proved to be ineffective six months later, with recurrence of bacilloscopy positivity. In 2009/11, a new therapeutic regimen was introduced with SEEtZ. After eight months, treatment failure was diagnosed with positive bacilloscopy. A second strain (F2) was then isolated (2011/08) and showed resistance to isoniazid, and a new therapeutic regimen was introduced with AEOTZ. The treatment was successfully completed after 18 months with clinical cure (Figure 7).

The MIRU-VNTR and spoligotyping data were identical for both isolates, F1 and F2 (Table 2), in addition the WGS presented a difference of 3.6 SNPs/year (Table 3). These genotypic data allowed us to infer that all episodes of disease were caused by the same strain [19, 52-56].

The WGS data analysis detected a S315T mutation in the katG gene, described as associated with resistance to isoniazid [88-99]. This mutation was identified in 100% of the population of the strain phenotypically resistant to isoniazid (F2) (Table 4).

4. DISCUSSION
Here, by molecular and phenotypic approaches, we studied *M. tuberculosis* strains obtained from six patients with different histories of TB retreatment, including cases of abandonment and therapeutic failure and relapse. Previously TB treatment was a major risk factor for DR TB, and resistant strain subpopulations were selected by exposure to drugs through ineffective therapeutic regimens [100-103].

DST by phenotypic methods has the advantage of detecting drug resistance independent of the associated molecular basis. However, they are laborious and can present late results. In this study, we used the BATEC 320 MGIT system, while PM was routinely used. Some discrepancies between these methods were observed, and the resistances (C1 for isoniazid, B1 and B2 for streptomycin) were undetectable by PM. Although PM is low-cost, its accuracy in detecting drug resistance is lower than that of other phenotypic methods, such as MGIT or Resazurin microtiter assays, as well as molecular methods [104-107].

In this study, WGS allowed the identification of mutations in the *katG*, *rpsL* and *rpoB* genes, associated with resistance to isoniazid, streptomycin and rifampicin, respectively [58, 72, 81, 86, 87, 90, 94]. Furthermore, we identified DR subpopulations that can be imperceptible by phenotypic methods. Streptomycin resistance was identified in 29% of the population of B1 and B2 strains; however, this resistance was undetectable by phenotypic methods. This may be related to mutations that confer a low level of drug resistance (border line), the presence of more than one strain in the same clinical sample [106, 108, 109], or that the population of strains extracted from the crop and that was used in the STD may not represent the total population [25, 110]. Black et al. (2015) showed that the selection of only one to three single colonies for each patient isolate would have limited the analysis of the true heterogeneity in the total population and resulted in the loss of variants representing susceptible colonies.

S315T (*katG* gene), the most common mutation reported to be associated with resistance to isoniazid [88-99], was detected in the F2 strain. In addition, rare mutations in the *katG* gene associated with resistance were also identified at codons D735Y, Y337C and N138H in different strains. Although the introduction of a line probe assay in routine diagnosis for detecting isoniazid-resistant *M. tuberculosis* is useful to control TB cases, it should be considered that these commercial platforms do not detect rare mutations, and thus WGS and/or phenotypic methods should be part of the investigation of DR TB [35, 57-63, 75, 79-81, 112].

Furthermore, in relation to the position at codon 735 in the *katG* gene, in A1, there was an amino acid variation of D to a stop codon, but the strain continued to be susceptible to INH. However, in A2, a part of the population (41%) presented a mutation at position 2153907 in relation to A1, and the strain became resistant. Previous studies have reported that mutations at this codon (735) occur in the C-terminal domain of the *katG* gene, a site that is required for catalase activity. Thus, in general,
mutations in the katG gene at this position are associated with a reduction in catalase enzyme activity [57, 60, 61, 63]. In this way, we evaluated the activity of the catalase enzyme in strains A1 and A2, and the results showed a loss of enzymatic activity in strain A2. This fact can explain the presence of a mutation in the promotor region of the ahpC gene in strain A2, which is considered a compensatory mutation to hyperexpression of ahpC, an alkyl peroxidase that also protects bacilli against the toxic effects of organic peroxides. All these results were confirmed in a new culture of both strains from the stock tube, with new genomic DNA extraction, ahpC promoter and katG gene sequencing, minimal inhibitory concentration determination and catalase activity evaluation [57, 60, 61, 63, 88, 90].

Analyzing the docking results, we observed that the mutants A1 (D735X) and A2 (D735Y) and katG wt presented different results in terms of the best INH docking region scored, showing the impact of the mutations in katG-INH interactions (Table 6 and Figure 2). In addition, when we compared A1 (D735X) with HEM (Figure 2C) and A2 (D735Y) with HEM (Figure 2E) interactions, we noticed a hydrogen bond between TRP107 in A2 (D735Y) and INH that was not present in A1 D735X-INH. According to Mo et al., this amino acid is an important residue of the Met255-Tyr229-Trp107 triad conserved in many catalase peroxidases next to HEM, and TRP 107 plays a crucial role in compound reductions mediated by \( \text{H}_2\text{O}_2 \) [113,114]; thus, this difference can explain, at least in part, the differences observed in the susceptibility tests.

It is important to mention that we could not observe more differences between katG mutants because we performed protein docking simulations with rigid receptors; thus, the impact of mutations on protein flexibility was not properly considered. In future work, we will perform molecular dynamics simulations to evaluate the impact of these mutations on receptor structures and flexibility [113,114].

The E2 strain, the unique MDR strain of this study, was rifampicin resistant with a mutation in the 81 bp RRDR of the rpoB gene (H445D) [81-86, 115]. Its previous strain (E1) only had the mutation N138H in the katG gene, which, although rare, had already been described as being related to isoniazid resistance [60, 79-81]. Resistance to isoniazid generally arises before rifampicin resistance, and its early detection could help control MDR tuberculosis.

Mutations in the rpoC gene have been proposed to be compensatory mutations by rifampin resistance-conferring mutations in the rpoB gene. However, in this study, we found the mutation G594E in the rpoC gene in strains isolated from patients with resistance (E) and susceptibility to rifampicin (A and D). This mutation was previously described as a marker specific for the Haarlem lineage [64] and not associated with rifampicin resistance because it is also present in isolates susceptible and resistant to rifampicin [65-67].
According to the data obtained by WGS and SpolPred, patient D presented TB with two genetically distinct strains during the period evaluated. Genetic variation was determined by WGS, and 266 SNPs between D1 and D2 were identified, indicating the occurrence of exogenous reinfection [14, 36, 41, 52, 76-78]. Interestingly, 24 loci MIRU-VNTR that present discriminatory power higher than spoligotyping did not differentiate D1 and D2 strains. However, the spoligotype profiles presented by the SpolPred tool showed the absence of a single spacer, and this fact could be a systematic tool error, as already reported in previous studies [36, 42, 78].

Patient D was a prisoner during treatment, a site of overpopulation and high TB burden, which can facilitate infection with more than one strain of *M. tuberculosis*. In addition, the patient was a user of crack cocaine, which can predispose to immunosuppression [14, 78, 116-119].

In conclusion, sequencing technologies can improve TB control by detecting rare and new mutations related to detection of drug resistance, as well as identifying subpopulations of DR strains allowing early clinical and therapeutic intervention. In addition, WGS can unequivocally identify diverse populations of strains, allowing the detection of exogenous reinfection cases, which is particularly important due to the high burden of TB and drug resistance [24, 76, 120].
References


Tables

Table 1. Clinical and epidemiological data from the six patients studied

<table>
<thead>
<tr>
<th>Patients</th>
<th>Gender</th>
<th>Alcoholic</th>
<th>Smoker</th>
<th>Drug user</th>
<th>HIV</th>
<th>HCV</th>
<th>HBsAg</th>
<th>Diabetes</th>
<th>Prisoner</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Male</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>B</td>
<td>Female</td>
<td>*</td>
<td>*</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>C</td>
<td>Male</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>D</td>
<td>Male</td>
<td>No</td>
<td>*</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>E</td>
<td>Male</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>Male</td>
<td>Yes</td>
<td>*</td>
<td>*</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>


Table 2. Genotypic profile of the *Mycobacterium tuberculosis* strains by the MIRU-VNTR and Spoligotyping methods

<table>
<thead>
<tr>
<th>Samples</th>
<th>MIRU-VNTR</th>
<th>SPOLIGOTYPING</th>
<th>SIT</th>
<th>CLADE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>254343332493254221136243</td>
<td>777776777760601</td>
<td>137</td>
<td>X2</td>
</tr>
<tr>
<td>A2</td>
<td>254343332493254221136243</td>
<td>777776777760601</td>
<td>137</td>
<td>X2</td>
</tr>
<tr>
<td>B1</td>
<td>263142232432241221234223</td>
<td>677777607760771</td>
<td>20</td>
<td>LAM1</td>
</tr>
<tr>
<td>B2</td>
<td>263142232432241221234223</td>
<td>677777607760771</td>
<td>20</td>
<td>LAM1</td>
</tr>
<tr>
<td>B3</td>
<td>263142232432241221234223</td>
<td>677777607760771</td>
<td>20</td>
<td>LAM1</td>
</tr>
<tr>
<td>C1</td>
<td>252333332553262221234233</td>
<td>777777777760700</td>
<td>51</td>
<td>T1</td>
</tr>
<tr>
<td>C2</td>
<td>252333332553262221234233</td>
<td>777777777760700</td>
<td>51</td>
<td>T1</td>
</tr>
<tr>
<td>D1</td>
<td>244345332373254221334233</td>
<td>777777777760671</td>
<td>245</td>
<td>T1</td>
</tr>
<tr>
<td>D2</td>
<td>244345332373254221334233</td>
<td>777777777760471</td>
<td>65</td>
<td>T1</td>
</tr>
<tr>
<td>E1</td>
<td>244345332373254221334233</td>
<td>777777777760471</td>
<td>65</td>
<td>T1</td>
</tr>
<tr>
<td>E2</td>
<td>244345332373254221334233</td>
<td>777777777760471</td>
<td>65</td>
<td>T1</td>
</tr>
<tr>
<td>F1</td>
<td>263142234442251221234123</td>
<td>677737607760711</td>
<td>179</td>
<td>LAM2</td>
</tr>
<tr>
<td>F2</td>
<td>263142234442251221234123</td>
<td>677737607760711</td>
<td>179</td>
<td>LAM2</td>
</tr>
</tbody>
</table>

MIRU-VNTR: mycobacterial interspersed repetitive units-variable number of tandem repeat, SIT: spoligotype international type.
Table 3. Difference of Single Nucleotide Polymorphisms (SNPs) among serial isolates of *Mycobacterium tuberculosis*

<table>
<thead>
<tr>
<th>Sample/Patient</th>
<th>SNP distance (number)</th>
<th>Time between isolation (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1/A2</td>
<td>1</td>
<td>0.25</td>
</tr>
<tr>
<td>B1/B2</td>
<td>0</td>
<td>0.75</td>
</tr>
<tr>
<td>B2/B3</td>
<td>3</td>
<td>1.1</td>
</tr>
<tr>
<td>C1/C2</td>
<td>0</td>
<td>0.3</td>
</tr>
<tr>
<td>D1/D2</td>
<td>266</td>
<td>1.3</td>
</tr>
<tr>
<td>E1/E2</td>
<td>2</td>
<td>0.6</td>
</tr>
<tr>
<td>F1/F2</td>
<td>4</td>
<td>1.1</td>
</tr>
</tbody>
</table>

SNP: single nucleotide polymorphism.
Table 4. SNPs in genes related to antibiotic resistance and the percentage of base composition in all mapped reads from each position

<table>
<thead>
<tr>
<th>Patient</th>
<th>Position</th>
<th>Mutation</th>
<th>Gene</th>
<th>Reference</th>
<th>A (%)</th>
<th>C (%)</th>
<th>G (%)</th>
<th>T (%)</th>
<th>Phenotypic Resistance</th>
<th>A (%)</th>
<th>C (%)</th>
<th>G (%)</th>
<th>T (%)</th>
<th>Phenotypic Resistance</th>
<th>A (%)</th>
<th>C (%)</th>
<th>G (%)</th>
<th>T (%)</th>
<th>Phenotypic Resistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>765150</td>
<td>C-54T</td>
<td>ahpC</td>
<td></td>
<td>C</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2153907</td>
<td>G594E</td>
<td>rpoC</td>
<td></td>
<td>G</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
<td>0</td>
<td>41</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2153909</td>
<td>D735X*Y</td>
<td>katG</td>
<td></td>
<td>G</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>41</td>
<td>59</td>
<td>0</td>
<td></td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>781687</td>
<td>K43R</td>
<td>rpsL</td>
<td></td>
<td>A</td>
<td>71</td>
<td>0</td>
<td>29</td>
<td>0</td>
<td>71</td>
<td>0</td>
<td>29</td>
<td>0</td>
<td>STR</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>STR</td>
</tr>
<tr>
<td>C</td>
<td>2155102</td>
<td>Y337C</td>
<td>katG</td>
<td></td>
<td>T</td>
<td>0</td>
<td>99</td>
<td>1</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>INH</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>INH</td>
</tr>
<tr>
<td>D</td>
<td>765150</td>
<td>G594E</td>
<td>rpoC</td>
<td></td>
<td>G</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>INH</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>INH</td>
</tr>
<tr>
<td></td>
<td>2155700</td>
<td>N138H</td>
<td>katG</td>
<td></td>
<td>T</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>MDR</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>MDR</td>
</tr>
<tr>
<td>E</td>
<td>761139</td>
<td>H445D</td>
<td>rpoB</td>
<td></td>
<td>C</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>INH</td>
<td>99</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>MDR</td>
</tr>
<tr>
<td></td>
<td>765150</td>
<td>G594E</td>
<td>rpoC</td>
<td></td>
<td>G</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>INH</td>
<td>99</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>MDR</td>
</tr>
<tr>
<td></td>
<td>2155700</td>
<td>N138H</td>
<td>katG</td>
<td></td>
<td>T</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>INH</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>INH</td>
</tr>
</tbody>
</table>

*Point mutations in positions 2153907 and 2153909 that together resulted in a stop codon (X). These positions in WGS are showed in antisense and in complement strand. INH: isoniazid, MDR: multidrug-resistant, S: susceptible, SNP: single nucleotide polymorphism, STR: streptomycin.
Table 5. Confirmatory results related to the molecular and phenotypic variation of A1 and A2 strains

<table>
<thead>
<tr>
<th>Strain</th>
<th>INH MIC (µg/mL)</th>
<th>Catalase activity</th>
<th>Sequencing by Sanger Method</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>ahpC</td>
</tr>
<tr>
<td>H37Rv</td>
<td>0.25</td>
<td>+</td>
<td>Wt</td>
</tr>
<tr>
<td>A1</td>
<td>0.125</td>
<td>+</td>
<td>Wt</td>
</tr>
<tr>
<td>A2</td>
<td>16.0</td>
<td>-</td>
<td>C-54T</td>
</tr>
</tbody>
</table>

INH: isoniazid, MIC: minimal inhibitory concentration, WT: wild type.

Table 6. Free energy of binding predicted by molecular docking simulations with Vina and approximated final docked position

<table>
<thead>
<tr>
<th>Gene/Strain</th>
<th>With HEM</th>
<th>Without HEM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Score (in kcal/mol)</td>
<td>Amino acids / HEM interacting with INH</td>
</tr>
<tr>
<td>katG H37Rv wt</td>
<td>-6.5</td>
<td>PRO422, LYS488, GLY490, ASN493, ASP 735, ASP738</td>
</tr>
<tr>
<td>katG D735X</td>
<td>-6.5</td>
<td>HEM, ASP137, ILE228, TYR229, VAL230, PRO232,</td>
</tr>
<tr>
<td>katG D735Y</td>
<td>-7.0</td>
<td>HEM, TRP107, ASP137, PRO232</td>
</tr>
</tbody>
</table>

Captions to illustrations

<table>
<thead>
<tr>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>11</td>
<td>11</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>L</td>
<td>L</td>
<td>L</td>
<td>L</td>
</tr>
<tr>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>T</td>
<td>T</td>
<td>T</td>
<td>T</td>
</tr>
<tr>
<td>Z</td>
<td>Z</td>
<td>Z</td>
<td>Z</td>
</tr>
</tbody>
</table>

Resistant to H

**Figure 1.** Treatment history and susceptibility profile of first-line anti-TB drugs by BATEC 320 MGIT system from patient A. E: ethambutol, H: isoniazid, L: levofloxacin, R: rifampicin, S: streptomycin, T: terizidone, Z: pyrazinamide. ▲: abandonment treatment, ■: treatment cure, ♦: treatment failure, +: positive bacilloscopy, −: negative bacilloscopy. Letters in box are the strains isolated.
Figure 2. The best docking positions for INH-katG. (A) katG wt with HEM-INH, (B) katG wt-INH, (C) A1 D735X with HEM-INH, (D) A1 D735X-INH, (E) A2 D735Y with HEM-INH, (F) A2 D735Y-INH. The katG amino acids are labeled in green, where we highlighted in yellow in (A) and (B) the Asp 735 (the point mutation). HEM is colored in red. INH is in the center of the figures. The colors of the bonds in dotted lines corresponds to: green (conventional hydrogen bond), light green (carbon hydrogen bond or Pi-donor hydrogen bond), orange (Pi-anion), magenta (Pi-sigma or Pi-Pi stacked), rose (Pi-alkyl). Figure and analyses generated by Discovery Studio.
**Figure 3.** Treatment history and susceptibility profile of first-line anti-TB drugs by BATEC 320 MGIT system from patient B. A: amikacin, E: ethambutol, Et: ethionamide, H: isoniazid, O: ofloxacin, R: rifampicin, S: streptomycin, T: terizidone, Z: pyrazinamide. ▲: abandonment treatment, ■: treatment cure, ♦: treatment failure, +: positive bacilloscopy, −: negative bacilloscopy. Letters in box are the strains isolated.

**Figure 4.** Treatment history and susceptibility profile of first-line anti-TB drugs by BATEC 320 MGIT system from patient C. E: ethambutol, H: isoniazid, L: levofloxacin, R: rifampicin, S: streptomycin, T: terizidone, Z: pyrazinamide. ▲: abandonment treatment, ■: treatment cure, ♦: treatment failure, +: positive bacilloscopy, −: negative bacilloscopy. Letters in box are the strains isolated.
**Figure 5.** Treatment history and susceptibility profile of first-line anti-TB drugs by BATEC 320 MGIT system from patient D. E: ethambutol, H: isoniazid, L: levofloxacin, R: rifampicin, S: streptomycin, T: terizidone, Z: pyrazinamide. ▲: abandonment treatment, ■: treatment cure, ♦: treatment failure, +: positive bacilloscopy, −: negative bacilloscopy. Letters in box are the strains isolated.

<table>
<thead>
<tr>
<th>2008</th>
<th>D1</th>
<th>2009</th>
<th>D2</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>R</td>
<td>H</td>
<td>L</td>
<td>R</td>
<td>H</td>
<td>R</td>
<td>L</td>
</tr>
<tr>
<td>Z</td>
<td>S</td>
<td>T</td>
<td>Z</td>
<td>S</td>
<td>T</td>
<td>Z</td>
</tr>
<tr>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
</tr>
</tbody>
</table>

**Figure 6.** Treatment history and susceptibility profile of first-line anti-TB drugs by BATEC 320 MGIT system from patient E. A: amikacin, E: ethambutol, Et: ethionamide, H: isoniazid, L: levofloxacin, R: rifampicin, S: streptomycin, T: terizidone, Z: pyrazinamide. ▲: abandonment treatment, ■: treatment cure, ♦: treatment failure, +: positive bacilloscopy, −: negative bacilloscopy. Letters in box are the strains isolated.

<table>
<thead>
<tr>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>7</td>
<td>9</td>
<td>30</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>R</td>
<td>S</td>
<td>E</td>
<td>S</td>
<td>E</td>
<td>S</td>
<td>E</td>
<td>S</td>
</tr>
<tr>
<td>Z</td>
<td>S</td>
<td>E</td>
<td>S</td>
<td>E</td>
<td>S</td>
<td>E</td>
<td>S</td>
</tr>
<tr>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
<td>̶</td>
</tr>
</tbody>
</table>

Time (months)
**Figure 7.** Treatment history and susceptibility profile of first-line anti-TB drugs by BATEC 320 MGIT system from patient F. A: amikacin, E: ethambutol, Et: ethionamide, H: isoniazid, O: ofloxacin, R: rifampicin, S: streptomycin, T: terizidone, Z: pyrazinamide. ▲: abandonment treatment, ■: treatment cure, ◆: treatment failure, +: positive bacilloscopy, −: negative bacilloscopy. Letters in box are the strains isolated.
**Funding**: JLCGD was a Fellow of Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), PEAS is a Fellow of **Conselho Nacional de Desenvolvimento Científico e Tecnológico** (CNPq) productivity. The study had financial support by Project **CNPq/Universal (401963/2016-0)**, **CAPES** (PVE-CAPES, 88881.064961/2014-01) and iMed.ULisboa from Fundação para a Ciência e Tecnologia (SFRH/BPD/95406/2013). JEP is funded by a Newton Institutional Links Grant (British Council, no. 261868591). TGC is funded by the Medical Research Council UK (Grant no. MR/M01360X/1, MR/N010469/1, MR/R025576/1, and MR/R020973/1) and BBSRC (Grant no. BB/R013063/1). SC is funded by Medical Research Council UK grants (ref. MR/M01360X/1, MR/R025576/1, and MR/R020973/1).

**Competing interests**: The authors report no conflicts of interest.

**Ethical approval**: This work was approved by the Research Ethics Committee of the State Foundation for Production and Health Research (n. 04/2012).